BG Medicine, Inc. announced that the first automated version of the BGM Galectin-3(R) blood test has obtained a CE Mark. The BGM Galectin-3 test will be distributed through bioM rieux's VIDAS(R) immunoassay platform which includes about 27,000 installed instruments worldwide. bioM rieux is one of four diagnostic instrument manufacturers partnering with BG Medicine to commercialize automated versions of the BGM Galectin-3 test, and the first to obtain a CE Mark.

bioM rieux is preparing a phased launch of the test in Europe and in certain other territories that recognize the CE Mark. The CE Mark for bioM rieux's automated version of the BGM Galectin-3 test is the latest in a series of steps designed to further BG Medicine's three-pillared business model for the test, which is focused on rapid commercial adoption driven by sales through automated partners, specialized labs and the targeting of US hospitals with high readmissions rates.